Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

d explanation is lack of specificity of Trasylol®.

TXA and EACA are lysine analogs that function as competitive inhibitors of plasminogen activation and, at much higher concentrations, noncompetitive inhibitors of plasmin.  These agents are considered to be safer but less effective than Trasylol®. While TXA is approximately 10 times more potent than EACA, it is associated with a fourfold increase over EACA in the risk of seizures.  Further, a study demonstrated that patients administered TXA required more transfusion product than patients who were administered Trasylol®, resulting in significantly higher overall transfusion-related costs for patients treated with the less expensive, generic agent TXA.  

Omeros' proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of Factor XIa and kallikrein. This selectivity could provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immunological side effects.

About Omeros' Antifibrinolytic Program

Omeros is developing a series of novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma. Omeros' agents are designed to selectively inhibit plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of Factor XIa and kallikrein, important regulators of the coagulation cascade. These agents could provide a superior replacement for the antifibrinolytic agents Trasylol® (aprotinin), tranexamic acid and epsilon aminocaproic acid. The selectivity of Omeros' agents may provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immuno
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: Germany ... 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- EDGE Orthopaedics, a new entry in ... announce they have received their second FDA 510(k) ... Fracture Plating System. The VIEW Plating ... indications within the mid-foot. The system includes titanium ... (CC), Talonavicular (TN) and Evans plates along with ...
(Date:8/28/2014)... CITY , Aug. 28, 2014 /PRNewswire-iReach/ -- Academy ... by service academy graduates, has published a case ... three-day Leadership Excellence Course . In September and ... Excellence Course to Albuquerque , Indianapolis ... . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... Cancer Journal , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--Introgen,Therapeutics, ... the dramatic clinical benefit of its lead product,Advexin ... of cancer known as,Li-Fraumeni Syndrome (LFS), a genetic ... suppressor gene. This is the,first reported treatment of ...
... CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead,Sciences, ... III,AIR-CF1 (CP-AI-007) study of aztreonam lysine for ... fibrosis (CF) who have,pulmonary Pseudomonas aeruginosa (P. ... at Day 28 from baseline in respiratory,symptoms, ...
Cached Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... -- Researchers have discovered that people with dyslexia have ... the most commonly diagnosed learning disorder in the United ... Previous research showed that brain activity is disrupted in ... only on a small number of brain regions. ... multiple brain regions use networks to communicate with each ...
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 For ... Research Foundation (Meso Foundation) will be observing September 26th ... on Rockefeller Plaza, in New York. , Members ... encouraged to RSVP . The Foundation will be providing ... the past years, mesothelioma community members have received attention ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Bedros Keuilian recently ... boot camp marketing expert on the new Spike TV ... Keuilian when they searched Google for an expert in boot ... Keuilian’s YouTube videos. Now Keuilian has just released a webinar ... build their own status as experts and increase their client ...
(Date:8/29/2014)... 29, 2014 TayganPoint Consulting Group, a ... the second time, Inc. Magazine has named the company ... , Based on solid revenue growth of over 166% ... overall on the list. TayganPoint’s repeat success in ... the past few years, is a demonstration of its ...
Breaking Medicine News(10 mins):Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 2Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 3
... of Psychiatry at Case Western Reserve University School of Medicine ... Institute of Mental Health (NIMH) for the long-term study of ... NIMH, one of the National Institutes of Health (NIH), funds ... which 707 children between the ages of six and 12 ...
... By Maryann Mott HealthDay Reporter , THURSDAY, ... twice before snuggling in bed at night with Fido or ... issue of the public health journal Emerging Infectious Diseases ... that cause mild to life-threatening illness in people. Of ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay ... greatly increases the chances of dying, new research ... analysis, of previously published studies that looked at ... Six of seven studies found pre-existing diabetes was ...
... (HealthDay News) -- Many young American couples can,t agree on ... a new study shows. Oregon State University researchers analyzed ... 18 to 25. In 40 percent of those couples, one ... the other partner said there was no such deal. ...
... paper published Jan. 21 in the journal Science , ... Blossom Damania, PhD, has shown for the first time that ... a key molecule involved in the human immune response. ... Kenan, Jr. Distinguished Professor, Jenny Ting, PhD. First ...
... Ky. Healthcare workers can most directly affect quality of ... helping manage symptoms such as pain, lack of energy, shortness ... a study recently published in the journal Oncology Nursing ... or the degree to which a symptom bothers a person, ...
Cached Medicine News:Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 2Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 3Health News:Pets May Pass Illnesses to Owners 2Health News:Pets May Pass Illnesses to Owners 3Health News:Breast Cancer Patients With Diabetes May Fare Worse 2Health News:Breast Cancer Patients With Diabetes May Fare Worse 3Health News:Young Couples Often Disagree About Monogamy, Study Finds 2Health News:Viral protein mimic keeps immune system quiet 2Health News:Controlling symptoms can lead to improved quality of life for end-of-life patients 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: